Antibodies

09 Nov 2020 Xencor Presents Updated Data From the DUET-2 Phase 1 Study of XmAb20717, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual Meeting
09 Nov 2020 Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the SITC Annual Meeting
09 Nov 2020 AC Immune and WuXi Biologics Strengthen Strategic Partnership to Accelerate AC Immune’s Anti-TDP-43 Antibodies into Clinical Development
09 Nov 2020 BioInvent presents new preclinical data on BI-1808, a first-in-class anti-TNFR2 antibody at the SITC 35[th] Anniversary Annual Meeting
09 Nov 2020 Merck Announces Out-Licensing Agreement for Investigational Atacicept with Vera Therapeutics
09 Nov 2020 Amgen Presents First Clinical Data for AMG 757 at SITC 2020
09 Nov 2020 New Preclinical Data being Presented at SITC Underscore Promising Combinations of Affimed’s AFM13 and Cytokine-Activated Natural Killer Cells
09 Nov 2020 Pierre Fabre initiates a "First in Human" clinical trial for an innovative monoclonal antibody (W0180) targeting the VISTA checkpoint in patients..
07 Nov 2020 Update on FDA Advisory Committee’s Meeting on Aducanumab in Alzheimer’s Disease
06 Nov 2020 Vir Biotechnology Publishes New Research Characterizing Variation in the SARS-CoV-2 Spike Protein and Virulence of a Prevalent Immune Evasion Variant, N439K
06 Nov 2020 Equillium Announces Positive Interim Data of Itolizumab in the First-line Treatment of Acute Graft-Versus-Host Disease
06 Nov 2020 Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for First-Line Treatment of Metastatic Non-Small Cell Lung Cancer
06 Nov 2020 Viela Bio Announces Final Results from Phase 1b Trial of VIB7734 in Patients with Cutaneous Lupus Erythematosus
06 Nov 2020 Celltrion presents efficacy and safety data for potential COVID-19 treatment candidate CT-P59 in patients with mild symptoms
06 Nov 2020 Novartis provides update on CAN-COVID trial in hospitalized patients with COVID-19 pneumonia and cytokine release syndrome (CRS)
05 Nov 2020 Genmab Announces Phase 3 Study Evaluating Epcoritamab in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
05 Nov 2020 Janssen Seeks Expanded Use of DARZALEX®▼ (daratumumab) Subcutaneous Formulation for the Treatment of Patients with Light Chain (AL) Amyloidosis
05 Nov 2020 Novartis Cosentyx® shows early synovitis reduction in patients with psoriatic arthritis in first-of-its-kind study
03 Nov 2020 Celltrion Healthcare Presents Positive Top-Line Efficacy and Safety Results for CT-P17 in the Treatment of Rheumatoid Arthritis
02 Nov 2020 European Commission approves Roche’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
02 Nov 2020 DESTINY-Breast05 Head-to-Head Phase 3 Trial of ENHERTU® Versus T-DM1 Initiated in Patients with HER2 Positive Early Breast Cancer at High Risk After Neo-adjuvant Therapy
02 Nov 2020 Novus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic Lateral Sclerosis
02 Nov 2020 Jounce Therapeutics Announces Update on Vopratelimab Program
02 Nov 2020 Ocumension Therapeutics Strengthens Pipeline for Posterior Segment Eye Diseases
31 Oct 2020 Bimekizumab Phase 3 Data Shows Superior Skin Clearance Over Humira^® in Moderate-to-Severe Psoriasis Patients

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top